Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity

Greenlee, 2001, Cancer statistics, 2001 [published correction appears in CA Cancer J Clin. 2001;51:144], CA Cancer J Clin, 51, 15, 10.3322/canjclin.51.1.15 Hideshima, 2002, Molecular mechanisms of novel therapeutic approaches for multiple myeloma, Nat Rev Cancer, 2, 927, 10.1038/nrc952 Richardson, 2002, Thalidomide: emerging role in cancer medicine, Annu Rev Med, 53, 629, 10.1146/annurev.med.53.082901.104043 Hideshima, 2000, Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy, Blood, 96, 2943, 10.1182/blood.V96.9.2943 Davies, 2001, Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma, Blood, 98, 210, 10.1182/blood.V98.1.210 Gupta, 2001, Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications, Leukemia, 15, 1950, 10.1038/sj.leu.2402295 Mitsiades, 2002, Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications, Blood, 99, 4525, 10.1182/blood.V99.12.4525 Lentzsch, 2002, S-3-amino-phthalimidoglutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice, Cancer Res, 62, 2300 Lentzsch, 2003, Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo, Leukemia, 17, 41, 10.1038/sj.leu.2402745 Singhal, 1999, Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342:364], N Engl J Med, 341, 1565, 10.1056/NEJM199911183412102 Rajkumar, 2000, Thalidomide in the treatment of relapsed multiple myeloma, Mayo Clin Proc, 75, 897, 10.4065/75.9.897 Barlogie, 2001, Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients, Blood, 98, 492, 10.1182/blood.V98.2.492 Kumar, 2003, Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma, Mayo Clin Proc, 78, 34, 10.4065/78.1.34 Weber, 2003, Thalidomide alone or with dexamethasone for previously untreated multiple myeloma, J Clin Oncol, 21, 16, 10.1200/JCO.2003.03.139 Rajkumar, 2002, Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma, J Clin Oncol, 20, 4319, 10.1200/JCO.2002.02.116 Durie, 2001, Low dose thalidomide alone and in combination: long term follow-up [abstract], Blood, 98, 163a Richardson, 2002, Thalidomide in multiple myeloma, Biomed Pharmacother, 56, 115, 10.1016/S0753-3322(02)00168-3 Richardson, 2002, Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma, Blood, 100, 3063, 10.1182/blood-2002-03-0996 Richardson, 2002, A multi-center, randomized, phase II study to evaluate the efficacy and safety of two CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed and refractory multiple myeloma (MM) [abstract], Blood, 100, 104a Richardson, 2003, Blood, 101, 235a